The continued climb of the U.S. dollar weighed heavily on pharmaceutical giant Johnson & Johnson's Johnson & Johnson's first quarter earnings reported Tuesday morning. It was in many ways a repeat of a quarter earlier — only this time the numbers were worse with currency woes cutting further into international sales, profitability and now the company’s outlook on the coming three quarters.
The New Brunswick, NJ based company reported $17.4 billion in first quarter revenue, down 4.1% from the same period a year ago. While sales increased 5.9% at home, sales abroad declined 12.4%, reflecting a negative currency impact of 13.2%. One bright point is that revenue was a bit higher than anal...
Also read: Who's in charge of outer space?